Most cited papers from Fundació ACE

Fundació ACE

What are the most cited papers from Fundació ACE?

The most cited paper from Fundació ACE is "Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease" (European Alzheimer's Disease Initiative (EADI) et al., 2013), with 4,711 citations. Next come "Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing" (3,277) and "New insights into the genetic etiology of Alzheimer’s disease and related dementias" (2,608).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 107 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease European Alzheimer's Disease Initiative (EADI) et al. · Nature Genetics ReviewOpen access184 authors	27 Oct 2013	4,711
2	Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing Brian W. Kunkle et al. · Nature Genetics ReviewOpen access469 authors	28 Feb 2019	3,277
3	New insights into the genetic etiology of Alzheimer’s disease and related dementias Céline Bellenguez et al. · Nature Genetics Open access1,266 authors	Apr 2022	2,608
4	Analysis of shared heritability in common disorders of the brain Verneri Anttila et al. · Science Open access577 authors	21 Jun 2018	2,056
5	The characterisation of subjective cognitive decline Frank Jessen, Rebecca England Amariglio, Rachel F. Buckley et al. · The Lancet Neurology Open access	17 Jan 2020	1,435
6	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease Valentina Escott‐Price et al. · PLoS ONE Open access188 authors	12 Jun 2014	1,408
7	Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization Jean Marc Orgogozo, Sid Gilman, Jean‐François Dartigues et al. · Neurology	8 Jul 2003	1,351
8	Mapping the human genetic architecture of COVID-19 COVID-19 Host Genetics Initiative et al. · Nature Open access3,896 authors	8 Jul 2021	1,130
9	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease Rebecca C. Sims et al. · Nature Genetics Open access450 authors	17 Jul 2017	1,122
10	Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease Lawrence S. Honig et al. · New England Journal of Medicine Open access	25 Jan 2018	1,070
11	Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease Scott Neu et al. · JAMA Neurology Open access	28 Aug 2017	691
12	A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease for the SCarlet RoAD Investigators, Susanne Ostrowitzki, Robert A. Lasser et al. · Alzheimer s Research & Therapy Open access	Dec 2017	576
13	Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease Isidró Ferrer, Merçé Boada, María Luisa Sánchez Guerra et al. · Brain Pathology Open access	2004	571
14	A Phase II Trial of Tideglusib in Alzheimer's Disease Simon Lovestone, for the ARGO investigators, Merçé Boada et al. · Journal of Alzheimer s Disease	3 Mar 2015	532
15	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies Laura A. Rabin et al. · Journal of Alzheimer s Disease Open access	24 Sep 2015	475
16	Frontotemporal dementia and its subtypes: a genome-wide association study Raffaele Ferrari et al. · The Lancet Neurology Open access158 authors	18 Jun 2014	410
17	Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders Ellen Gelpí, Judith Navarro‐Otano, EDUARDO S. TOLOSA et al. · Movement Disorders	2 Jan 2014	369
18	Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores Itziar de Rojas et al. · Nature Communications Open access572 authors	7 Jun 2021	350
19	A novel Alzheimer disease locus located near the gene encoding tau protein Gyungah Jun et al. · Molecular Psychiatry Open access429 authors	17 Mar 2015	315
20	The impact of the COVID-19 pandemic on the mental health of healthcare professionals María Dolores Braquehais, Sebastián Vargas-Cáceres, Esperanza L. Gómez‐Durán et al. · QJM Open access	13 Jun 2020	312
21	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum Willemijn J. Jansen et al. · JAMA Neurology Open access183 authors	31 Jan 2022	308
22	Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials Rik R. Vandenberghe et al. · Alzheimer s Research & Therapy Open access	12 May 2016	304
23	Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease Susanne Ostrowitzki et al. · JAMA Neurology Open access	19 Sep 2022	237
24	A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease Lluís Tárraga · Journal of Neurology Neurosurgery & Psychiatry Open access	16 Jun 2006	233
25	A Bluetooth Low Energy Indoor Positioning System with Channel Diversity, Weighted Trilateration and Kalman Filtering Vicente Cantón Paterna, Anna Calveras, Josep Paradells et al. · Sensors Open access	16 Dec 2017	230
26	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP Rita João Guerreiro et al. · Neurobiology of Aging Open access	31 Jul 2008	219
27	Early Detection of Mild Cognitive Impairment (MCI) in Primary Care Marwan Noel Sabbagh, Merçé Boada, Soo Borson et al. · The Journal of Prevention of Alzheimer s Disease Open access	Jun 2020	216
28	Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia Sílvia Alonso-Lana, Marta Marquié, Agustı́n Ruiz et al. · Frontiers in Aging Neuroscience Open access	26 Oct 2020	215
29	Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease Alette M. Wessels et al. · JAMA Neurology Open access	25 Nov 2019	215
30	Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia David A. Bergeron et al. · Annals of Neurology Open access	26 Sep 2018	208
31	Convergent genetic and expression data implicate immunity in Alzheimer's disease Lesley Jones et al. · Alzheimer s & Dementia Open access187 authors	19 Dec 2014	208
32	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved Ana Espinosa, Montserrat Alegret, Sergi Valero et al. · Journal of Alzheimer s Disease	4 Mar 2013	184
33	Genome‐wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project Sonia Moreno–Grau et al. · Alzheimer s & Dementia Open access192 authors	28 Aug 2019	182
34	Sensitivity of European wheat to extreme weather Hanna Mäkinen, Janne Kaseva, Miroslav Trnka et al. · Field Crops Research Open access	21 Nov 2017	167
35	Incidence and consequences of falls among elderly people living in the community Antoni Salvà, Ignasi Bolíbar, Guillem Pera et al. · Medicina Clínica	2004	165
36	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia Vivek Swarup et al. · Nature Medicine Open access174 authors	28 Nov 2018	157
37	European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders Giovanni Battista Frisoni et al. · The Lancet Neurology Open access	14 Feb 2024	156
38	Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers Iris E. Jansen et al. · Acta Neuropathologica Open access147 authors	6 Sep 2022	147
39	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study Merçé Boada, Oscar L. López, Javier Olazarán et al. · Alzheimer s & Dementia Open access	27 Jul 2020	145
40	Infant exposure of perfluorinated compounds: Levels in breast milk and commercial baby food Marta Llorca, Marinella Farré, Yolanda Picó et al. · Environment International	22 May 2010	143
41	Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study Hana Florian, Deli Wang, Steven Edward Arnold et al. · Brain Open access	24 Jan 2023	142
42	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity Sven J. van der Lee et al. · Acta Neuropathologica Open access105 authors	26 May 2019	132
43	Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study Virginia Pérez‐Grijalba, Judith Romero, Pedro Pesini et al. · The Journal of Prevention of Alzheimer s Disease Open access	2019	132
44	[Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI)]. Merçé Boada, Juan Carlos Cejudo, Lluís Tárraga et al. · PubMed	29 Jan 2003	129
45	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges Amanda C. Cano, Patric Turowski, Miren Ettcheto et al. · Journal of Nanobiotechnology Open access	29 Apr 2021	126
46	A second update on mapping the human genetic architecture of COVID-19 The COVID-19 Host Genetics Initiative et al. · Nature Open access3,885 authors	6 Sep 2023	125
47	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia Agustı́n Ruiz et al. · Neurobiology of Aging	13 Sep 2013	122
48	Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease Dolores Siedlecki‐Wullich, Judit Català-Solsona, Cristina Fábregas et al. · Alzheimer s Research & Therapy Open access	15 May 2019	119
49	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration Julie van der Zee et al. · Acta Neuropathologica Open access	4 Jun 2014	119
50	Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study Lourdes Mateu et al. · The Lancet Regional Health - Europe Open access	5 Sep 2023	117

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.